Table 3.
Cox regression models for the association of the combination of Tyg index and SHR with clinical outcomes
| Groups | P for trend | ||||
|---|---|---|---|---|---|
| Low TyG and low SHR | Low TyG and high SHR | High TyG and low SHR | High TyG and high SHR | ||
| CV death and TVMI | |||||
| No/subject | 13/1353 | 7/460 | 7/455 | 20/472 | |
| Crude | 1.00 | 1.55 (0.62–3.89) | 1.60 (0.64–4.00) | 4.49 (2.23–9.02) | < 0.001 |
| Model 1 | 1.00 | 1.67 (0.67–4.19) | 2.01 (0.79–5.08) | 5.09 (2.51–10.29) | < 0.001 |
| Model 2 | 1.00 | 1.96 (0.77–5.00) | 2.35 (0.91–6.08) | 6.40 (2.92–14.05) | < 0.001 |
| Model 3 | 1.00 | 2.24 (0.82–6.13) | 2.42 (0.83–7.06) | 7.16 (2.90–17.69) | < 0.001 |
| MACCEs | |||||
| No/subject | 60/1353 | 26/460 | 19/455 | 64/472 | |
| Crude | 1.00 | 1.26 (0.79–1.99) | 1.02 (0.55–1.55) | 3.28 (2.30–4.66) | < 0.001 |
| Model 1 | 1.00 | 1.29 (0.81–2.05) | 1.05 (0.62–1.76) | 3.54 (2.48–5.06) | < 0.001 |
| Model 2 | 1.00 | 1.38 (0.87–2.2) | 1.16 (0.68–1.96) | 4.07 (2.75–6.02) | < 0.001 |
| Model 3 | 1.00 | 1.48 (0.88–2.47) | 1.25 (0.71–2.19) | 3.62 (2.32–5.64) | < 0.001 |
Model 1: adjusted for age, sex, and BMI
Model 2: adjusted for age, sex, BMI, smoking, T2DM, dyslipidemia, hypertension, prior HF, prior MI, prior stroke, peripheral vascular disease, prior revascularization, and AMI
Model 3: age, sex, BMI, smoking, HF, T2DM, dyslipidemia, hypertension, prior MI, prior stroke, peripheral vascular disease, prior revascularization, AMI, multivessel disease, ostial lesion, bifurcation, number of lesions ≥ 2, number of stents ≥ 2, procedural success, eGFR, DAPT, statin, and anti-diabetic drug
Low TyG index or SHR: T1-2; High Tyg index or SHR: T3
TyG triglyceride-glucose, CV cardiovascular, eGFR estimated glomerular filtration rate, MI myocardial infarction, MACCEs major adverse cardiovascular cerebral events, SHR stress-hyperglycemia ratio, BMI body mass index, T2DM type 2 diabetes mellitus, HF heart failure, AMI acute myocardial infarction, DAPT dual anti-platelet therapy